
Glycocholic acid-d₅

MedChemExpress

| Cat. No.: | HY-N1423S | 1 | |
|--------------------|---|-------|----------|
| CAS No.: | 2170091-95 | -7 | |
| Molecular Formula: | C ₂₆ H ₃₈ D ₅ NO | 6 | |
| Molecular Weight: | 470.65 | | |
| Target: | Endogenous Metabolite; Isotope-Labeled Compounds | | |
| Pathway: | Metabolic Enzyme/Protease; Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

Product Data Sheet



| | BIOLOGICAL ACTIVITY | | | | | |
|--|---------------------|--|--|--|--|--|
| | | | | | | |
| | Description | Glycocholic acid-d ₅ is the deuterium labeled Glycocholic acid. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways ^[1] . | | | | |
| | In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | |

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[3]. Lo YL, et al. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci. 2008 Sep 2;35(1-2):52-67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA